Summit Therapeutics Inc.
A clinical-stage biopharmaceutical company founded in 2003 in Oxford, England, that develops new medicines for serious diseases — starting with antibiotics and later shifting its focus to cancer treatments such as the lung-cancer drug ivonescimab. It went through a string of odd early names, including CobraDragon and Vastox, before settling on "Summit," a nod to reaching the peak of healthcare. Today it is listed on Nasdaq and runs offices in Miami, California, and the UK.
Sponsored American Depositary Shares (ADS)
Bought 3.91M
Bought 3.91M
Bought 50.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Duggan Robert WCo-Chief Executive Officer, Director, 10% owner · 2 transactions | — | 1.76B | — | 3.91M | — |
| Zanganeh MahkamCo-Chief Executive Officer, Director, 10% owner · 2 transactions | +0.6% | 610.02M | — | 3.91M | — |
| Soni Manmeet SinghCOO and CFO, Director · 2 transactions | +0.8% | 3.10M | — | 50.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +7.87M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.